So, thats the difficulty here
Younossi ZM, Golabi P, de Avila L et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis
Triple agonists including retatrutide show exceptional promise based on remarkable weight loss and liver fat normalization in early trials, with dedicated MASH histology studies ongoing
A lot of these issues could potentially be avoided with an oral option. Pills Wont Suit Every Patient Still, not everyone will find orforglipron patient friendly because you need to take it every day
Mounjaro is administered as a once-weekly subcutaneous injection , starting at 2.5 mg for 4 weeks (for tolerability, not glycaemic control)
Therefore, they share the same half-life of approximately seven days